American Herbal Products Association (AHPA) > News > Latest News

AHPA’s 40 Herbs We Love – No. 9: Oshá (with ❤️ from Vitality Works)

May 2022: Celebrating AHPA’s 40th anniversary with 40 of our favorite herbs

AHPA’s 40th anniversary celebrations continue with our showcase of the eighth of many beloved herbs at the heart of our robust industry and vibrant community.

AHPA gives feedback on Senate HELP Committee MPL proposal

May 2022: AHPA Update

The American Herbal Products Association (AHPA) has offered feedback on mandatory product listing (MPL) provisions included in a recently released “discussion draft” of the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, a piece of must-pass legislation that reauthorizes drug and medical device user fee programs.

FDA releases NDI enforcement discretion draft guidance

May 2022: Final guidance will provide opening for NDI notification “catch-up submissions”

FDA has released a draft guidance outlining a proposed policy of enforcement discretion regarding the late submission of new dietary ingredient (NDI) notifications. Upon the release of a finalized guidance, companies will be able to electronically submit late NDIs to FDA for a set period (currently 180 days in the draft guidance) without penalty.

Initial AHPA time study results suggest nearly $20 million initial compliance price tag for Durbin/Braun product listing bill

May 2022: Early data do not include initial training costs or follow-on costs for label revisions or new products

The American Herbal Products Association (AHPA) has estimated the dietary supplement industry will need to spend nearly 20 million dollars for initial compliance with the Dietary Supplement Listing Act, a bill introduced by Senators Richard Durbin (D-IL) and Mike Braun (R-IN) that would establish a requirement for mandatory product listing (MPL) for all dietary supplements marketed in the United States.

Senate HELP Committee publishes draft bill including MPL, new cosmetics regulations

May 2022: AHPA Update

The United States Senate Committee on Health, Education, Labor and Pensions (HELP) has released a “discussion draft” of the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act, a piece of must-pass legislation that reauthorizes drug and medical device user fee programs.

AHPA’s 40 Herbs We Love – No. 8: Goldenseal (with ❤️ from Native Botanicals)

May 2022: Celebrating AHPA’s 40th anniversary with 40 of our favorite herbs

AHPA’s 40th anniversary celebrations continue with our showcase of the eighth of many beloved herbs at the heart of our robust industry and vibrant community.

AHPA’s 40 Herbs We Love – No. 7: Lemon Balm (with ❤️ from Four Elements Organic Herbals)

May 2022: Celebrating AHPA’s 40th anniversary with 40 of our favorite herbs

AHPA’s 40th anniversary celebrations continue with our showcase of the seventh of many beloved herbs at the heart of our robust industry and vibrant community.

May 2022 AHPA Report

AHPA Members, Log in to access the AHPA Report

The May 2022 AHPA Report includes: A message from the new AHPA Board Chair, 40ᵗʰ Anniversary Guest Feature by Jane Hawley Stevens, upcoming AHPA webinars, 40 Herbs We Love; and more!

AHPA’s 40 Herbs We Love – No. 6: Ashwagandha (with ❤️ from Banyan Botanicals)

April 2022: Celebrating AHPA’s 40th anniversary with 40 of our favorite herbs

AHPA’s 40th anniversary celebrations continue with our showcase of the sixth of many beloved herbs at the heart of our robust industry and vibrant community.

AHPA Webinar - cGMP Facility Inspections Conducted by FDA: How Inspection Ready Are You?

June 15, 2022 – 10am-12pm PT / 1-3pm ET

This webinar is designed to help businesses in the dietary supplement industry understand the elements of current Good Manufacturing Practice (cGMP) regulations (21 CFR 111) that are the primary focus during U.S. Food and Drug Administration (FDA) facility inspections.

RSS
12345678910 Last

2022 Annual Fund Sponsors

AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.